Literature DB >> 32409376

Tocilizumab-induced pulmonary fibrosis in a patient with rheumatoid arthritis.

Sanjeeva Silva1, Roshan Amarasena1, Jim Moorcroft2, Tharshini Rajakulenthiran1, Ruchir Singh1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32409376      PMCID: PMC7243567          DOI: 10.7861/clinmed.20-2-s57

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


× No keyword cloud information.
  2 in total

Review 1.  Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.

Authors:  Jasvinder A Singh; Chris Cameron; Shahrzad Noorbaloochi; Tyler Cullis; Matthew Tucker; Robin Christensen; Elizabeth Tanjong Ghogomu; Doug Coyle; Tammy Clifford; Peter Tugwell; George A Wells
Journal:  Lancet       Date:  2015-05-11       Impact factor: 79.321

Review 2.  Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review.

Authors:  Camille Roubille; Boulos Haraoui
Journal:  Semin Arthritis Rheum       Date:  2013-10-05       Impact factor: 5.532

  2 in total
  3 in total

Review 1.  Thinking inside the box: Current insights into targeting orbital tissue remodeling and inflammation in thyroid eye disease.

Authors:  Vardaan Gupta; Christine L Hammond; Elisa Roztocil; Mithra O Gonzalez; Steven E Feldon; Collynn F Woeller
Journal:  Surv Ophthalmol       Date:  2021-09-04       Impact factor: 6.197

Review 2.  Immune-related adverse events of biological immunotherapies used in COVID-19.

Authors:  Daniela Baracaldo-Santamaría; Giovanna María Barros-Arias; Felipe Hernández-Guerrero; Alejandra De-La-Torre; Carlos-Alberto Calderon-Ospina
Journal:  Front Pharmacol       Date:  2022-08-25       Impact factor: 5.988

Review 3.  New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of roflumilast in treating COVID-19.

Authors:  Manar Mohammed El Tabaa; Maram Mohammed El Tabaa
Journal:  Eur J Pharmacol       Date:  2020-10-01       Impact factor: 4.432

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.